Company profile
Essen Biotech
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CD123 / CD33Cell therapy | Acute Myeloid Leukemia | |
| Phase 1/2 | Tumor antigen menu (TROP2, MSLN, B7-H3, HER2)Cell therapy | Multiple Myeloma | |
| Phase 1/2 | Personalized, biomarker-guided allogeneic chimeric antigen receptorCell therapy | Multiple Myeloma |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.